A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia …
T Kühr, S Burgstaller, U Apfelbeck, W Linkesch… - Leukemia Research, 2003 - Elsevier
This multicenter randomized phase III study was designed to compare the efficacy and
toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10mg/m2 d1-10) or …
toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10mg/m2 d1-10) or …
A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the …
FJ Giles, J Shan, S Chen, SH Advani… - Leukemia & …, 2000 - Taylor & Francis
A prospective randomized international study of 143 patients showed no apparent early
survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as …
survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as …
A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia
M Baccarani, G Rosti, A de Vivo… - Blood, The Journal …, 2002 - ashpublications.org
Interferon-α (IFN-α) has significantly prolonged survival in chronic myeloid leukemia (CML),
but some patients do not respond and many responses are not durable. To improve the …
but some patients do not respond and many responses are not durable. To improve the …
Interferon-α Combined with Cytarabine in Chronic Myelogenous Leukemia-Clinical Benefits
M Lindauer, T Fischer - Leukemia & Lymphoma, 2001 - Taylor & Francis
During the last decade, several studies have evaluated the treatment of chronic phase
chronic myeloid leukemia (CML) with a combination of interferon (IFN)-α and low-dose …
chronic myeloid leukemia (CML) with a combination of interferon (IFN)-α and low-dose …
Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON …
HC Kluin-Nelemans, G Buck, S le Cessie, S Richards… - Blood, 2004 - ashpublications.org
The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML) is unknown.
Retrospective analyses suggest that low doses are as effective as high doses, with less …
Retrospective analyses suggest that low doses are as effective as high doses, with less …
Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia
The French Chronic Myeloid Leukemia Study Group prospective randomized study results
indicate that the addition of cytarabine to alpha interferon (IFN-α) increases the rate of major …
indicate that the addition of cytarabine to alpha interferon (IFN-α) increases the rate of major …
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study
W Deenik, B van der Holt, GEG Verhoef… - Annals of …, 2007 - Springer
A prospective randomized phase III study was performed to evaluate whether intensified
cytarabine would induce a higher response rate and longer event-free interval as compared …
cytarabine would induce a higher response rate and longer event-free interval as compared …
[HTML][HTML] A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses
MJ Penarrubia, J Odriozola, C Gonzalez… - Annals of …, 2003 - Springer
Abstract Interferon-alpha (IFN-α) is a therapy of unquestionable efficacy in chronic myeloid
leukemia (CML) patients. The best dose of IFN-α in the treatment of CML still remains …
leukemia (CML) patients. The best dose of IFN-α in the treatment of CML still remains …
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study …
RT Silver, BL Peterson, TP Szatrowski… - Leukemia & …, 2003 - Taylor & Francis
Despite nine studies reporting the results achieved when treating patients with chronic
myeloid leukemia (CML) with interferon (rIFN α) and cytarabine (araC), the optimal doses …
myeloid leukemia (CML) with interferon (rIFN α) and cytarabine (araC), the optimal doses …
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multicenter phase II study
J Thaler, W Hilbe, U Apfelbeck, W Linkesch, H Sill… - Leukemia research, 1997 - Elsevier
Small pilot studies of patients with CML have reported on encouraging response rates after
treatment with interferon-alpha (IFNα) in combination with low-dose cytosine arabinoside …
treatment with interferon-alpha (IFNα) in combination with low-dose cytosine arabinoside …